Currently, the PARP inhibitor, olaparib is approved for the adjuvant treatment of adult patients with germline BRCA-mutated HER2-negative high-risk early BC who have been treated with neoadjuvant or adjuvant chemotherapy based on the results of the OlympiA trial (110, 111). This evidence concerns the gene ERBB2 and breast cancer.